Stockscreener 앱 받기
6.14
1.99%
0.12
시간 외 거래:
6.42
0.28
+4.56%
전일 마감가:
$6.02
열려 있는:
$6.15
하루 거래량:
2,338
Relative Volume:
0.18
시가총액:
$58.71M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+3.72%
1개월 성능:
+4.07%
6개월 성능:
+20.39%
1년 성능:
+0.00%
1일 변동 폭
$6.02
$6.36
1주일 범위
$5.5001
$6.36
52주 변동 폭
$3.81
$10.28
Serina Therapeutics Inc Stock (SER) Company Profile
명칭
Serina Therapeutics Inc
전화
(256) 327-9630
주소
601 GENOME WAY, HUNTSVILLE
SER을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
6.14 | 58.71M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Serina Therapeutics Inc 주식(SER)의 최신 뉴스
Juvenescence Lands $76M Funding and M42 Partnership to Transform Drug Development in Abu Dhabi - Stock Titan
UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42 - GlobeNewswire Inc.
VivaTech 2025: A record-setting edition with 180,000 visitors - The Globe and Mail
Serina Therapeutics Congratulates Juvenescence on Securing $150 Million Series B Financing and Strategic Alliance with M42 - Nasdaq
Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42 - GlobeNewswire
$150M Biotech Deal: Juvenescence Partners With M42 to Launch AI-Powered Drug Hub in Abu Dhabi - Stock Titan
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?" - StreetInsider
Registration Is Now Open For Tribe Public’s CEO - GlobeNewswire
Biotech Bear Market Creates Massive Opportunity: 25% of US Firms Trading Below Enterprise Value - Stock Titan
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients - The Globe and Mail
Nvidia's Big Moment Is Just Ahead. Here's What to Watch For. - The Globe and Mail
Serina Therapeutics Appoints Dr. Stephen Brannan to Board of Directors to Enhance CNS Therapeutic Development - Nasdaq
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors - The Manila Times
Karuna's $14B Exit Architect Joins Serina Board: CNS Drug Development Expert to Guide Neural Pipeline - Stock Titan
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan - GlobeNewswire
Parkinson's Drug Developer Serina Therapeutics Expands Team with Equity Incentives Worth 15,000 Shares - Stock Titan
JonesTrading Keeps Their Buy Rating on Serina Therapeutics (SER) - The Globe and Mail
Serina Therapeutics Advances SER-252 for Parkinson’s Disease and Strengthens Leadership and Financial Position - Nasdaq
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - The Globe and Mail
Serina Therapeutics to Present at JonesResearch Virtual CNS Day - The Manila Times
Serina Therapeutics CEO to Showcase Revolutionary CNS Drug Technology: Key Presentation Details Revealed - Stock Titan
Serina Therapeutics Says May Offer And Sell Shares Of Common Stock Of Up To $13.3 Million - marketscreener.com
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit - GlobeNewswire
Revolutionary Drug Delivery Tech Could Make mRNA Vaccines Safer: New Trial Data - Stock Titan
Serina Therapeutics closes $5 million funding for Parkinson’s trial By Investing.com - Investing.com Canada
Serina Therapeutics Secures $5 Million Funding - MarketScreener
Serina Therapeutics closes $5 million funding for Parkinson’s trial - Investing.com
Serina Therapeutics Secures $5 Million in Funding to - GlobeNewswire
Revolutionary Parkinson's Treatment Gets $5M Boost: Serina's New Drug Heads to Clinical Trials - Stock Titan
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - GlobeNewswire
Serina's Game-Changing POZ Platform Takes Center Stage at Major Healthcare Conference - Stock Titan
Serina Therapeutics Files For Mixed Shelf Of Upto $100 MillionSEC Filing - MarketScreener
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Serina Therapeutics to Present Novel Data on Non-Immunogenic Lipid Nanoparticles at ACS Spring 2025 Meeting - Nasdaq
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting - GlobeNewswire
Jones Trading Initiates Coverage of Serina Therapeutics (SER) with Buy Recommendation - Nasdaq
Serina Therapeutics initiated with a Buy at JonesResearch - TipRanks
Serina Therapeutics Appoints Dr. Venkatesan to Board - TipRanks
Serina Therapeutics Appoints Dr. Jay Venkatesan to Board of Directors - Nasdaq
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors - GlobeNewswire
Former Alpine Immune Sciences Founder Who Led $4.9B Exit Takes Board Seat at Serina - StockTitan
Huntsville biotech firm partnering with Pfizer lands $10 million for Parkinson’s trial - MSN
Serina secures additional $5 million for Parkinson's trial - MSN
Earnings To Watch: e.l.f. Beauty (ELF) Reports Q4 Results Tomorrow - The Globe and Mail
Serina secures additional $5 million for Parkinson's trial By Investing.com - Investing.com Australia
Stocks to Watch: Palantir Technologies, Synaptics, J&J Snack Foods, Serina Therapeutics - MarketWatch
Serina Therapeutics's Shares Up Following $5M of Equity Financing - MarketWatch
Serina Therapeutics Receives Second $5 Mln Tranche To Strengthen Cash Position - Marketscreener.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Serina Therapeutics receives funding to advance SER-252 into clinical trial - TipRanks
Serina Therapeutics Inc (SER) 재무 분석
Serina Therapeutics Inc (SER)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Serina Therapeutics Inc 주식 (SER) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bailey Gregory | Director |
Sep 20 '24 |
Buy |
6.03 |
1,137 |
6,851 |
63,377 |
| Bailey Gregory | Director |
Sep 19 '24 |
Buy |
6.11 |
11,679 |
71,384 |
62,240 |
| Bailey Gregory | Director |
Sep 18 '24 |
Buy |
6.23 |
2,709 |
16,873 |
50,561 |
| MINTZ STEVEN | Director |
Sep 12 '24 |
Buy |
6.47 |
6,000 |
38,814 |
17,443 |
| Bailey Gregory | Director |
Aug 20 '24 |
Buy |
8.25 |
1,776 |
14,652 |
47,582 |
| Bailey Gregory | Director |
Aug 19 '24 |
Buy |
7.93 |
6,400 |
50,760 |
45,806 |
| Bailey Gregory | Director |
Aug 16 '24 |
Buy |
7.31 |
6,400 |
46,780 |
39,406 |
| Bailey Gregory | Director |
Aug 15 '24 |
Buy |
6.65 |
6,400 |
42,577 |
33,006 |
| MINTZ STEVEN | Director |
Aug 15 '24 |
Buy |
6.59 |
7,593 |
50,033 |
11,443 |
| MINTZ STEVEN | Director |
Aug 15 '24 |
Buy |
6.59 |
1,350 |
8,896 |
12,257 |
1.45%
0.86%
자본화:
|
볼륨(24시간):